Etoposide | 2020 | II | Resistant/Refractory Ovarian cancer | 200mg daily | To be initiated | |
M4344 – ATR inhibitor | 2020 | I/II | Resistant/Recurrent Ovarian cancer | Starting with 100mg, escalating to 200mg | To be initiated | |
Brivanib | 2019 | I | Recurrent Ovarian cancer | 100mg or 200 mg, daily | Recruiting | |
Dostarlimab – anti-PD-1 | 2018 | III | 1st line non-mucinous Ovarian cancer | 300mg daily | Recruiting | |
Cobimetinib +/Atezolizumab | 2018 | Ib | Platinum sensitive ovarian cancer | 200mg daily | Recruiting | |
TSR-042 anti-PD-1 | 2019 | II | Recurrent platinum-resistant Ovarian cancer | N/A | Recruiting | |
Bevacizumab | 2019 | I/II | Ovarian cancer, Platinum-sensitive | 300mg D1-21 | PFS benefit with the combination [11,9 months (95% CI 8,5–16,7) vs 5,5 months (3,8 – 6,3)], HR 0,35 (95% CI 0·21–0·57), p<000,1 |
|
BAY1895344 ATR inhibitor | 2020 | Ib | PARPi naïve and with a platinum-resistant/refractory disease or PD after PARPi maintenance | N/A | Recruiting | |
Dostarlimab and bevacizumab | 2018 | II | Recurrent Ovarian cancer | 200mg or 300mg daily | Active – not recruiting- no results yet | |
bevacizumab | 2018 | II | Platinum sensitive Ovarian cancer | 300mg daily | Active – not recruiting- no results yet | |
Atezolizumab | 2018 | III | Platinum sensitive relapse | 200mg or 300mg daily | Recruiting | |
Pebrolizumab | I/II | Triple negative Breast cancer or recurrent ovarian cancer | 200mg | ORR of 25% in all PROC and ORR of 45% in tBRCAmut patients, well tolerated |
||
Everolimus | 2017 | I | Recurrent ovarian or breast cancer | 100mg or200mg or 300mg daily | Recruiting | |
Copanlisib | 2018 | I | Endometrial and Ovarian cancer | Escalating dose | Recruiting |
Carboplatin/Paclitaxel +/− Bevacizumab | 2018 | II | Resistant/Refractory Ovarian cancer | 400mg or 500mg 0r 600mg BID |
Recruiting | |
Nivolumab | 2018 | I/II | Platinum Sensitive Ovarian cancer | 600mg BID | Recruiting | |
Ipatasertib (Akt inhibitor) | 2019 | Ib | Breast, Prostate and Ovarian cancer | 600mg BID | Recruiting | |
Nivolumab and bevacizumab | 2016 | II | 2nd line Ovarian cancer | 600mg BID | Recruiting | |
Lucitanib (VEGF 1–3 inhibitor) or Sacituzumab (anti-Trop-2 monoclonal antibody linked with SN-38) | 2019 | I/II | Solid tumors | 600mg BID | Recruiting | |
Nivolumab | 2019 | II | Platinum sensitive recurrent Ovarian cancer | N/A | Active/not Recruiting | |
Mirvetuximab Soravtansine (olate receptor alpha targeting antibody-drug conjugate) | 2018 | I | Recurrent Ovarian cancer | 600mg BID | Recruiting | |
BAY1895344 ATR inhibitor | 2020 | Ib | PARPi naïve and with a platinum-resistant/refractory disease or PD after PARPi maintenance | N/A | Recruiting | |
Dostarlimab and bevacizumab | 2018 | II | Recurrent Ovarian cancer | 200mg or 300mg daily | Active – not recruiting- no results yet | |
bevacizumab | 2018 | II | Platinum sensitive Ovarian cancer | 300mg daily | Active – not recruiting- no results yet |
Durvalumab | 2018 | I | Solid tumors | |
ATR kinase inhibitor AZD6738 | 2019 | II | Solid tumors | |
Tremelimumab | 2020 | I | Recurrent or persistent ovarian cancer | |
Durvalumab and tremelimumab | 2016 | II | Recurrent or resistant Mbrca Ovarian cancer | |
Pebrolizummab | 2020 | II | Solid tumors, mHRD, dHRD | |
Selumetinib | 2017 | I/II | Endometrial, Ovarian cancer and other solid tumors | |
Ceralasertib (AZD6738) | 2018 | II | Recurrent Ovarian cancer | |
Adavosertib | 2018 | II | Ovarian cancer |
Topototecan | 2017 | I/II | Resistant/Partially Sensitive Ovarian cancer | 30 mg BID |
Well tolerated, Best response – SD in 37% | |
Temozolamide | 2018 | II | Recurrent Ovarian cancer | NA | Completed No Results yet | |
Carboplatin and Paclitaxel | 2019 | III | Newly diagnosed Ovarian cancer | Induction: 150 mg BID q21 |
PFS 23.5 vs 17.3 months (HR = 0.68; P < .001) | |
Paclitaxel-carboplatin | 2016 | I | Newly diagnosed Ovarian cancer | 100mg – 150mg BID q21 | Well tolerated/potential clinical benefit | |
Pegylated Liposomal Doxorubicin and carboplatin +/− bevacizumab | 2015 | I | Recurrent, platinum-sensitive ovarian cancer | 50mg or 80mg 0r 120mg | Well tolerated in low doses of veliparib | |
Capecitabine and oxaliplatin | 2014 | I | Solid tumors | 40mg BID days 1–7, 15–21, q28 | Well tolerated | |
Cyclophosphamide | 2016 | II | Refractory BRCA-Positive Ovarian Cancer and Breast cancer | 60mg daily | Well tolerated/no PFS benefit | |
Bevacizumab and Paclitaxel plus either carboplatin or IP cisplatin | 2009 | I | Ovarian cancer | N/A | Active-not recruiting |
Topotecan | 2009 | I | Solid tumors | Starting with cap 50mg BID |
Unacceptable toxicity | |
Dacarbazine | 2009 | I | Solid tumors | Cap 10mg BID continuously | Tolerated, no clinical benefit | |
Bevacizumab | 2015 | I | Solid tumors | Cap 400mg BID | Well tolerated | |
Lip-doxorubicin | 2017 | I | Ovarian cancer | Cap 150mg BID, continuously | Tolerated and clinical benefit | |
Paclitaxel | 2019 | I | Solid tumors | Tb 100mb BID | Reduce of olaparib bioavailability | |
Carboplatin and weekly paclitaxel | 2019 | Ib | Ovarian cancer | Tb 150mg BID continuously | Tolerated-clinical benefit in BRCAm | |
Lip-doxorubicin | 2019 | II | Ovarian cancer, Platinum-resistant | Tb 300mg BID continuously | Not recruiting, waiting for results | |
Carboplatin and paclitaxel | 2020 | II | Ovarian cancer-relapsed, platinum-sensitive | Cap 200mg BID continuously | PFS: 12.2 months (combo) vs 9.6 months (carboplatin/paclitaxel), HR : 0.51 (p=0.0012) OS: data not yet available |
C24H23FN43 | 434.5 | oral | 1–3hr | PARP1>PARP2 >>PARP3 | 5/1 | Tb 300mg BID |
5–11hr | |
C19H18FN3O | 323.4 | oral | 1.9hr | PARP1>PARP2 >>PARP3 And tankyrase inhibitor | 1.4 | Tb 600mg BID | 17–19hr | |
C19H20N4O | 320.4 | oral | 3hr | PARP1=PARP2 | 3.2/4 | 300mg once daily | 36hr | |
C13H16N4O | 244.29 | oral | 0.5 – 1.5hr | PARP1 PARP2 | 5.2/2.9 | Tb 400mg BID | 5.2hr | |
C19H14F2N6O | 380.4 | oral | 1–2hr | 1.2/0.9 | Cap 1mg daily | 90hr |